+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cough - Pipeline Review, H2 2019

  • ID: 4861702
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 99 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Antheia Inc
  • Bayer AG
  • Develco Pharma Schweiz AG
  • Grunenthal GmbH
  • NeRRe Therapeutics Ltd
  • Orbis Biosciences Inc
  • MORE
Cough - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H2 2019, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 10, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Antheia Inc
  • Bayer AG
  • Develco Pharma Schweiz AG
  • Grunenthal GmbH
  • NeRRe Therapeutics Ltd
  • Orbis Biosciences Inc
  • MORE
Introduction
Report Coverage
Cough - Overview
Cough - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cough - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cough - Companies Involved in Therapeutics Development
Alitair Pharmaceuticals Inc
Antheia Inc
Axalbion SA
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Charleston Laboratories Inc
Conrig Pharma ApS
Develco Pharma Schweiz AG
Evotec SE
Grunenthal GmbH
Hyundai Pharmaceutical Co Ltd
Merck & Co Inc
NeRRe Therapeutics Ltd
Nocion Therapeutics Inc
Orbis Biosciences Inc
PhytoHealth Corp
Roivant Sciences Ltd
Shionogi & Co Ltd
SolAeroMed Inc
Trevi Therapeutics Inc
Tris Pharma Inc
Cough - Drug Profiles
Ax-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AX-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1817080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1902607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzonatate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrocodone bitartrate + Undisclosed drug - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levodropropizine CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHCA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1226 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-600918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 for Endometriosis and Chronic Cough - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 for Endometriosis and Chronic Cough - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chronic Cough - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Cough - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Sodium Channels for Cough - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRN-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cough - Dormant Projects
Cough - Discontinued Products
Cough - Product Development Milestones
Featured News & Press Releases
Oct 02, 2019: Congress presentation on clinical study of S-600918, a drug candidate for the treatment of Refractory/Unexplained Chronic Cough
Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial
Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment
Jun 07, 2019: NeRRe Therapeutics announces positive findings from phase 2b study with orvepitant in chronic cough
May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society International Conference
May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences
May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937
Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients
Feb 28, 2019: Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cough, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Cough - Pipeline by Alitair Pharmaceuticals Inc, H2 2019
Cough - Pipeline by Antheia Inc, H2 2019
Cough - Pipeline by Axalbion SA, H2 2019
Cough - Pipeline by Bayer AG, H2 2019
Cough - Pipeline by Beijing Tide Pharmaceutical Co Ltd, H2 2019
Cough - Pipeline by Charleston Laboratories Inc, H2 2019
Cough - Pipeline by Conrig Pharma ApS, H2 2019
Cough - Pipeline by Develco Pharma Schweiz AG, H2 2019
Cough - Pipeline by Evotec SE, H2 2019
Cough - Pipeline by Grunenthal GmbH, H2 2019
Cough - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019
Cough - Pipeline by Merck & Co Inc, H2 2019
Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2019
Cough - Pipeline by Nocion Therapeutics Inc, H2 2019
Cough - Pipeline by Orbis Biosciences Inc, H2 2019
Cough - Pipeline by PhytoHealth Corp, H2 2019
Cough - Pipeline by Roivant Sciences Ltd, H2 2019
Cough - Pipeline by Shionogi & Co Ltd, H2 2019
Cough - Pipeline by SolAeroMed Inc, H2 2019
Cough - Pipeline by Trevi Therapeutics Inc, H2 2019
Cough - Pipeline by Tris Pharma Inc, H2 2019
Cough - Dormant Projects, H2 2019
Cough - Dormant Projects, H2 2019 (Contd..1), H2 2019
Cough - Dormant Projects, H2 2019 (Contd..2), H2 2019
Cough - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Cough, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alitair Pharmaceuticals Inc
  • Antheia Inc
  • Axalbion SA
  • Bayer AG
  • Beijing Tide Pharmaceutical Co Ltd
  • Charleston Laboratories Inc
  • Conrig Pharma ApS
  • Develco Pharma Schweiz AG
  • Evotec SE
  • Grunenthal GmbH
  • Hyundai Pharmaceutical Co Ltd
  • Merck & Co Inc
  • NeRRe Therapeutics Ltd
  • Nocion Therapeutics Inc
  • Orbis Biosciences Inc
  • PhytoHealth Corp
  • Roivant Sciences Ltd
  • Shionogi & Co Ltd
  • SolAeroMed Inc
  • Trevi Therapeutics Inc
  • Tris Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll